Xiang Liu to Ceramides
This is a "connection" page, showing publications Xiang Liu has written about Ceramides.
Connection Strength
0.923
-
LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria. J Pharmacol Exp Ther. 2013 Jan; 344(1):167-78.
Score: 0.331
-
Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol Ther. 2006 Nov; 14(5):637-46.
Score: 0.215
-
Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets. 2009 Dec; 13(12):1449-58.
Score: 0.068
-
Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther. 2009 Mar; 17(3):430-8.
Score: 0.064
-
Clinical relevance of ceramide metabolism in the pathogenesis of human head and neck squamous cell carcinoma (HNSCC): attenuation of C(18)-ceramide in HNSCC tumors correlates with lymphovascular invasion and nodal metastasis. Cancer Lett. 2007 Oct 18; 256(1):101-11.
Score: 0.057
-
The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther. 2007 Sep; 6(9):1455-60.
Score: 0.057
-
Involvement of sphingolipids in apoptin-induced cell killing. Mol Ther. 2006 Nov; 14(5):627-36.
Score: 0.054
-
Bioactive sphingolipid profile in a xenograft mouse model of head and neck squamous cell carcinoma. PLoS One. 2019; 14(4):e0215770.
Score: 0.032
-
Molecular targeting of acid ceramidase: implications to cancer therapy. Curr Drug Targets. 2008 Aug; 9(8):653-61.
Score: 0.015
-
Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol. 2008 Feb; 61(2):231-42.
Score: 0.014
-
Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. Mol Ther. 2007 Jul; 15(7):1259-63.
Score: 0.014